2022-85-7: Emtricitabine 5-Fluoro Cytosine
Also known as Emtricitabine Impurity 15, Emtricitabine IP Impurity E, Flucytosine or 4-Amino-5-fluoro-2(1H)-pyrimidine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) in combination with other antiviral agents it shows activity against HIV. It is approved for use in combination therapy.
Additional information on CAS 2022-85-7
VL54007
2022-85-7
C4H4FN3O
129.09
Emtricitabine
4-Amino-5-fluoro-2(1H)-pyrimidine
Emtricitabine Impurity 15; Emtricitabine IP Impurity E; Flucytosine; 4-Amino-5-fluoro-2(1H)-pyrimidine; Flucytosine, 5-FC; NSC 103805 6-Amino-5-fluoro-2(1H)-pyrimidinone
'Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.” Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://do
In-stock
